REGENXBIO IPO

9/17/2015

IPO

$138,600,000

We intend to use net proceeds from this offering, together with existing cash resources, as follows: approximately $15.0 million to fund external research and development expenses to advance our lead product candidate RGX-501 for the treatment of HoFH through Phase I/II clinical trials; approximately $13.0 million to fund external research and development expenses to advance our product candidate RGX-111 for the treatment of MPS I through Phase I/II clinical trials; approximately $10.0 million to fund external research and development expenses to advance our product candidate RGX-314 for the treatment of wet AMD through filing of an IND in preparation for a Phase I clinical trial; approximately $23.0 million to fund research and development expenses of our other internally developed product candidates and to identify and advance new programs or product candidates into preclinical studies; and the remainder for working capital, general and administrative expenses, internal research and

Publicly-held

Biopharmaceutical

9600 Blackwell Rd. 210
Rockville, MD 20850
USA

Not Recorded

REGENXBIO (NASDAQ: RGNX) is leveraging our proprietary NAV Technology to advance the development of life-changing adeno-associated viral (AAV) gene therapy treatments for lysosomal storage disorders and ocular diseases.